Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron Pharmaceuticals

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication

There's a lot to like about this big pharma juggernaut.

This Safe Stock Is Dirt Cheap -- and It's Beating the Market

BAE Systems PLC

Legal & General Group PLC

Unilever

U.S. equity markets aren't the only place where you can find income-producing royalty. Indeed, a quick look across the pond yields dozens, in the form of the European Dividend Aristocrats.

European Dividend Aristocrats: 40 Top International Dividend Stocks

A French court has ordered Sanofi to pay more than 400,000 euros ($416,440) in damages to a family whose child suffered from a form of autism caused by its epilepsy drug Valproate, saying the drugmaker failed to inform about known side effects.

Sanofi ordered to compensate French family for epilepsy drug side effects

AstraZeneca

Pfizer

These three pharma stocks each pay market-beating dividends to shareholders.

3 Top Biotech Stocks to Buy Right Now

Shares in EuroAPI, the drug ingredients business spun off from Sanofi, rose on their Paris stock market debut on Friday, defying a wider market decline.

EuroAPI gains on market debut after spin-off from Sanofi

Sanofi today launches Foundation S – The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations. Using donations, partnerships and collective action, Foundation S will focus on three critical areas: childhood cancer, the health of communities most vulnerable to the effects of climate change and pollution, and access to lifesaving medicines and vaccines.

Press Release: Foundation S: Sanofi's new philanthropic spearhead

Sanofi SA (NASDAQ:SNY ) Q1 2022 Earnings Conference Call April 28, 2022 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO & Director John Reed - EVP & Global Head, Research & Development William Sibold - EVP, Specialty Care & President, Sanofi North America Thomas Triomphe - Head, Vaccines Olivier Charmeil - Head, General Medicines Julie Van Ongevalle - EVP, Consumer Healthcare Jean-Baptiste de Chatillon - EVP & CFO Brendan O'Callaghan - EVP, Global Industrial Affairs Conference Call Participants Laura Sutcliffe - UBS Investment Bank Graham Parry - Bank of America Merrill Lynch Wimal Kapadia - Sanford C. Bernstein & Co. Luisa Hector - Berenberg Richard Vosser - JPMorgan Chase & Co. Timothy Anderson - Wolfe Research Peter Welford - Jefferies Keyur Parekh - Goldman Sachs Group Florent Cespedes - Societe Generale Mark Purcell - Morgan Stanley Peter Verdult - Citigroup Eva Schaefer-Jansen Good morning, good afternoon and good evening to everyone.

Sanofi SA (SNY) CEO Paul Hudson on Q1 2022 Results - Earnings Call Transcript

Sanofi (SNY) beats first-quarter estimates for earnings and sales. Dupixent drives sales growth along with strong recovery in travel vaccines.

Sanofi (SNY) Q1 Earnings Top, Vaccines Recover, CHC Sales Rise

Sanofi SA on Thursday posted higher earnings and sales for the first quarter, driven by best-selling drug Dupixent and consumer healthcare, and said that it expects further growth in business earnings per share during 2022.

Sanofi posts higher earnings and sales, sees further growth ahead

French healthcare group Sanofi's first quarter adjusted earnings gained 16.2% on continued sales growth of its bestselling drug Dupixent.

Sanofi operating income up 16% on bestseller drug Dupixent

Sanofi continues to deliver strong business EPS ( 1) growth driven by higher sales and improved margins in Q1

Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1

Emergent BioSolutions

Gilead Sciences

Eli Lilly

Merck

Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.

Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More

Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Sanofi (SNY) Ahead of Earnings?

Sanofi announces today that it is partnering with McLaren Racing to accelerate manufacturing efficiency and performance in support of the company's ambition to attain world-class standards of manufacturing excellence. Following a successful pilot in 2021 with McLaren Racing, both companies have decided to extend their collaboration across multiple sites in seven countries, covering more than 100 production lines, across all technologies. Learnings from this partnership will provide insights and develop best practices for manufacturing that will then be implemented across Sanofi's global industrial network .

Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence

Collaboration Supports Companies' Joint Focus on Medication Adherence and Affordability SAN FRANCISCO , April 13, 2022 /PRNewswire/ -- Today, Sempre Health announced compelling outcomes achieved during the first year of its collaboration with Sanofi (Nasdaq: SNY), an innovative global healthcare company. The results coming out of this collaboration have already led to health plans expanding their Sempre programs for 2022-2023.

Sempre Health Improved Medication Adherence by 25% for Diabetes Patients Prescribed Sanofi Medications

The Company's shareholders are invited to attend the Combined General Meeting to be held on Tuesday May 3, 2022 at 2:30 p.m. (CET) at Paris Expo Porte de Versailles – 1, Place de la Porte de Versailles, Hall 5.1 – 75015 Paris.

Sanofi - AGM 03.05.2022 - Availability of Preparatory Documents

The pharma giant recently shared encouraging results from a late-stage clinical trial for its hemophilia drug candidate.

Could This Drug Candidate Be a Blockbuster for Sanofi?

Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.

Regeneron (REGN), Sanofi's Dupixent Gets EU Nod for Asthma in Kids

Here we discuss some factors that have been driving Sanofi's (SNY) stock and its outlook for the future.

Sanofi (SNY) Stock Outperforms Industry YTD: What Lies Ahead?

The FDA accepts and grants priority review to Regeneron (REGN) and Sanofi's sBLA for Dupixent to treat eosinophilic esophagitis in patients aged 12 years and older. A decision is due on Aug 3, 2022.

Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA

Sanofi's DE&I strategy was revamped in June 2021 with set objectives toward 2025, built around three key pillars: building representative leadership, creating a work environment where employees can bring their whole selves and engaging with the company's diverse communities. The DE&I Board's role is to ensure Sanofi's DE&I strategy is rightly executed, to monitor progress on the company's 2025 targets and to advise on how to accelerate the company's impact in this space.

Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board

Sanofi expects to list its drug ingredients business EUROAPI on May 6, having received approval from French stock market regulator, the pharmaceutical giant said on Friday.

Sanofi to list drug ingredients business on May 6

Sanofi announced today that the French Autorité des marchés financiers (AMF) has approved the listing prospectus prepared by EUROAPI

Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022

IGM Biosciences Inc

A week filled with promising announcements failed to jump-start Sanofi SA's ( SNY , Financial) shares, but it did for the two companies it's working with.

News for Sanofi Stock (SNY)